YOUR #1 SOURCE FOR THE FASTEST MOVING NASDAQ AND NYSE LISTED STOCKS
YOUR #1 SOURCE FOR THE FASTEST MOVING NASDAQ AND NYSE LISTED STOCKS
stockreport.tips
A
Very frustrated with my significant investment in this stock. Will it ever see $20 rather $60, it's ATH?
s
$AA Target Raised by Morgan Stanley Equal Weight USD 12 » USD 14
T
buy ostk
T
buy gn
B
Nice to be positive on AA. I started buying in late January at an average of 13.9, including buying some $15 calls. Modest debt load and higher FCF from the liquid commodity grade product led me to think it was undervalued then. I'm planning to hold it until we see the mid 30's again but am willing to ride it out a couple years.
H
Any links can provide aluminum price daily for free? Thanks.
S
Cramer said he didn’t like Aloca at $5 and it’s triple since then. A 300% increase yet he still doesn’t like it. And he doesn’t admit that he was wrong we lost 300% because of him.
J
I wish I bought more when it was still at $6! But happy I bought what I did when I did! TY AA
T
Someone knows what happend ?? it was up 2.5% pre market ... and now is down 2.5% ?? tks
P
Not much gain in premarket.
J
Relief Therapeutics Chairman Sees Covid-19 Drug Earning Millions BY CATHERINE BOSLEY Aug. 8, 2020, 10:48 AM Selvaraju says there’s 60-70% chance of regulatory approval Sees annual peak revenue of hundreds of millions of dollars Relief Therapeutics’s chairman says the Swiss biotech stands to earn hundreds of millions of dollars if its drug Aviptadil gets a green light from regulators for treating Covid-19, according to an interview with The Market. Even with a vaccine, it’ll take some time to get people around the world inoculated, “so our drug would have a potential four to six years of use for patients who are seriously ill, and it could generate hundreds of millions of dollars per year during that time,” Chairman Raghuram Selvaraju was quoted as saying. The shares jumped more than 1,600% this week, when...
V
It is still a joke.
M
The big institutional investors each made big bucks yesterday ..$20 million on their 20 million shares ... not bad. Quite sure they plan to keep it and continue to experience the magic right through $25
H
AA reported performance for the second quarter of 2020 in line with the prefatory outcomes previously announced by the organization and demonstrated increased efficiency and sustained organizational stability during the COVID-19 pandemic. Also, check this company as it is flourishing and thriving in the cryptocurrency market. Learn HOW: http://psce.pw/DisruptingaMultiTrillionIndustryHotStocks
“According to McKinsey, the Global Payments industry is a $1.9 trillion-dollar industry.
“According to McKinsey, the Global Payments industry is a $1.9 trillion-dollar industry.
psce.pw
V
Zero future.
J
Tariff.... Whats everyone thoughts about this $AA stock now with imposed tariffs by both USA & Canada
T
buy telsa stock 400's now. Stock split
S
Any one got any dd on this company I bought 100 shares but financials looking forward in a year or so look good with there being an aluminum shortage right
https://stockreport.tips/Top-Market-Gainers
Target Raised by Morgan Stanley Equal Weight USD 12 » USD 14
tks
BY CATHERINE BOSLEY
Aug. 8, 2020, 10:48 AM
Selvaraju says there’s 60-70% chance of regulatory approval
Sees annual peak revenue of hundreds of millions of dollars
Relief Therapeutics’s chairman says the Swiss biotech stands to earn hundreds of millions of dollars if its drug Aviptadil gets a green light from regulators for treating Covid-19, according to an interview with The Market.
Even with a vaccine, it’ll take some time to get people around the world inoculated, “so our drug would have a potential four to six years of use for patients who are seriously ill, and it could generate hundreds of millions of dollars per year during that time,” Chairman Raghuram Selvaraju was quoted as saying.
The shares jumped more than 1,600% this week, when...